Austin-Headquartered Neurotech Maverick Reflects Upon Industry, Company Growth NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Dr. Connor Glass, CEO and Founder of Phantom Neuro, the company delivering breakthrough advancements in human-machine interface, will be speaking on the mainstage of this year's BioFuture™ 2025. The conference is hosted by Demy-Colton and held in New York City this October 13th through 15th. The innovative healthcare startup will be on stage among the likes of biotech, pharma, d

Clinically proven airway clearance solution now available; Company to showcase device at CHEST 2025 and NACFC 2025 JERSEY CITY, N.J. and OR YEHUDA, Israel, Oct. 8, 2025 /PRNewswire/ -- Synchrony Medical, a medical technology company dedicated to transforming respiratory care, announced today the launch of its LibAirty™ Airway Clearance System in the United States. The launch marks an important step forward for people living with chronic lung disease, providing access to advanced at-home therap

SAN FRANCISCO, Oct. 8, 2025 /PRNewswire/ -- Bunkerhill Health today announced that it has received U.S. Food and Drug Administration (FDA) clearance for Bunkerhill MAC, the first artificial intelligence algorithm to detect and quantify mitral annular calcification (MAC). The algorithm runs on routine, non-gated chest CT scans. Continue Reading MAC is a chronic condition in which calcium deposits build up in the mitral valve ring. Although often discovered incidentally, studies have linked MAC wi

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful moment

SAN ANTONIO, Oct. 8, 2025 /PRNewswire/ -- Sequence LifeScience Inc., a leader in allograft tissue processing, today announced a major milestone in its clinical development program: the first patient has been enrolled and treatment initiated in the company's innovative multicenter, prospective, matched controls clinical trial evaluating the safety of its placental membrane grafts for the treatment of diabetic foot ulcers (DFUs). The trial design is novel in that it employs a matched controls

BARCELONA, Spain, Oct. 8, 2025 /PRNewswire/ -- During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM 2025), C-Ray Therapeutics (Shanghai) Co., Ltd. ("C-Ray Shanghai"), a company dedicated to the development of innovative targeted radiopharmaceuticals, announced promising new clinical results for its lead program 225Ac-PSMA-CY313 in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Continue Reading These data, highlighted in two Top Rated

HOUSTON, Oct. 8, 2025 /PRNewswire/ -- DM Clinical Research, a leading multi-therapeutic site network, today announced the formation of its inaugural Advisory Board. Comprising respected leaders from clinical research and healthcare, the Board will provide strategic counsel to DM Clinical's Executive Leadership Team on growth priorities, operational excellence, and emerging trends shaping the future of clinical trials. "As we enter an exciting phase of growth, we are honored to partner with such

点击蓝字 ↑ 关注药研视角 PharmaView JMC速览 2025.10.01 近日，吉利德团队在药物化学权威期刊 Journal of Medicinal Chemistry 上发表了一篇题为 《发现Lenacapavir：首个HIV-1治疗与暴露前预防的半年一次给药的衣壳抑制剂》 的研究论文，系统阐述了全球首个获批的HIV衣壳抑制剂Lenacapavir的发现全过程。该研究历时十余年，从2006年启动高通量筛选，到最终开发出具有皮摩尔级抗病毒活性、支持每半年给药一次的长效小分子药物，突破了传统“蛋白-蛋白相互作用不可成药”的认知边界。论文详细解析了Lenacapavir如何通过独特的作用机制——加速衣壳异常组装并阻断病毒多阶段生命周期——实现对多重耐药HIV毒株的高效抑制，并兼具治疗与预防双重适应症。其研发历程不仅代表了抗病毒药物设计的里程碑，也为探索超大分子靶点的药物开发提供了范式转移级的科学启示。 1 min速览 研究背景 全球HIV/AIDS疫情依旧严峻：2023年仍有约1.3百万新感染、63万相关死亡，现有每日口服疗法依从性差异大，急需长效、耐药屏障高的新药。 衣壳蛋白

10月8日，圣地亚哥，Arthrosi Therapeutics，一家后期阶段生物技术公司，正在开发一种潜在的同类最佳、高效和选择性的下一代URAT1抑制剂，以降低痛风和痛风患者的血清尿酸盐（sUA）水平，缓解和溶解痛风，宣布完成1.53亿美元的E轮融资，该融资由Prime Eight Capital Limited领投，CR Biotech、HighLight Capital、HM Venture Partners、ReliantTech Limited和现有股东参与。一品红药业曾在2023年领导Arthrosi公司7500万美元D轮融资，氘泊替诺雷（AR882）中国区权益由一品红获得授权开发。9月30日，Crystalys Therapeutics仅靠一款URAT1抑制剂Dotinurad（多替诺雷）的部分权益融资超2亿美元。（新锐！2.05亿美元A轮融资，开发痛风新药） 氘泊替诺雷（AR882，基于苯溴马隆改造） Arthrosi计划利用这笔融资的收益，通过其关键的3期REDUCE 1和REDUCE 2研究，完成其核心项目pozdeutinurad（AR882）的临床开发，评估p

摘要：美国 FDA 于近日批准勃林格殷格翰旗下每日两次口服药 Jas cayd（通用名 nerandomilast），用于治疗特发性肺纤维化（IPF）。这是十多年来首款针对该罕见呼吸疾病的新疗法，为美国约 10 万 IPF 患者及每年 3 万 - 4 万新增患者带来新希望。药物获批基于 III 期临床数据，在肺功能改善上表现显著，安全性可控，同时也让 IPF 这一热门研发赛道的机遇与挑战再次进入视野。FDA 十年首肯：Jas cayd 填补 IPF 治疗空白 10 月 8 日，FDA 在公告中明确，Jas cayd 成为 IPF 领域十余年里首个新获批疗法。IPF 是一种罕见且进展性强的疾病，目前无法治愈，治疗选择也十分有限。 这种病会导致肺部小气囊周围组织增厚，进而形成永久性瘢痕，患者常出现呼吸困难、咳嗽等症状，高发人群集中在 60-70 岁。据统计，美国现有约 10 万 IPF 患者，每年新增确诊病例达 3 万 - 4 万。 不过，勃林格殷格翰暂未公布 Jas cayd 的上市时间与定价，患者何时能用上这款新药仍需等待。临床数据说话：肺功能改善显著，安全性可控 Jas cayd 的